Oncolytics Biotech Announces New Translational Data From An Ongoing Study Showing Pelareorep’s Ability To Increase HPV-16-Specific T Cell Clones And Tumor-Infiltrating Lymphocyte Clones In Second-Line Or Later Squamous Cell Anal Cancer Patients; Immune Activation Levels More Than Doubled In Nearly All Patients After One Cycle Of Treatment; Substantial Increases In HPV-16-Specific T Cells And Tumor-Infiltrating Lymphocytes Observed When Pelareorep Is Combined With A Checkpoint Inhibitor